Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYT107 in HIV patients with incomplete CD4 recovery on HAART
2010-019773-15Phase 2Terminated
- Sponsor
- Cytheris SA
- Start
- Jun 2010
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of recombinant human interleukin-7 in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Cytheris SA. Primary endpoints: Restoration and maintenance of CD4+ T-cell count above 500 cells/µL, Safety including HIV RNA viral load monitoring and 3 more. Started Jun 2010; status: terminated.
02
Drugs
recombinant human interleukin-7
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2010-019773-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019773-15.